Si-Tien Wang
Analysis Group
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Si-Tien Wang.
BJUI | 2010
Toni K. Choueiri; Mei Sheng Duh; Jessica M. Clement; A. J. Brick; Miranda Rogers; Christabel Kwabi; Karishma Shah; Andrew Percy; Lucia Antras; Sujata S. Jayawant; Kristina Chen; Si-Tien Wang; Andi Luka; Maureen P. Neary; David F. McDermott; William Oh
Study Type – Symptom prevalence (case series) Level of Evidence 4
Transfusion | 2010
Anastasios Raptis; Mei Sheng Duh; Si-Tien Wang; Ellison Dial; Ilias Fanourgiakis; Barry Fortner; Carole Paley; Nikita Mody-Patel; Mitra Corral; Jeffrey A. Scott
BACKGROUND: Patients with myelodysplastic syndrome (MDS) or severe anemia requiring repeated red blood cell (RBC) transfusions risk developing transfusional iron overload, which can reduce survival. Iron chelation therapy (ICT) has been shown to improve survival and quality of life in patients; however, ICT utilization in clinical practices is not well understood.
Leukemia & Lymphoma | 2012
Marie-Hélène Lafeuille; Francis Vekeman; Si-Tien Wang; Matthew Kerrigan; Laura Menditto; Mei Sheng Duh
Abstract This study estimated the average lifetime costs of patients with chronic lymphocytic leukemia (CLL) relative to similar patients without cancer. An analysis of the Medicare 5% database (1999–2007) was conducted. Each patient with CLL was matched up to three patients without cancer based on year of birth, gender, race and state. Average total lifetime costs were estimated using the Kaplan–Meier sample average estimator and stratified by treatments. For patients who died, average monthly costs during continuing and terminal phases were compared between cohorts. A total of 7463 patients with CLL and 22 331 matched controls were identified (mean age: 76 years; proportion of women: 49%). The mean observation period was 39.4 months for patients with CLL and 45.9 months for matched controls. Patients with CLL incurred average costs of
Medical Oncology | 2012
Bruce A. Feinberg; Pradeep Jolly; Si-Tien Wang; Barry Fortner; Jeffrey A. Scott; James Gilmore; Maureen P. Neary; Mei Sheng Duh
87 151 compared to
Blood | 2009
Philipp le Coutre; Anna G. Turkina; Dong-Wook Kim; B. Ceglarek; Giuliana Alimena; Haifa Kathrin Al-Ali; Zhixiang Shen; Graeme N. Smith; Carmino Antonio de Souza; Pedro Enrique Dorlhiac-Llacer; David A. Rizzieri; Tomasz Szczudlo; Myriam Berton; Jim Wang; Si-Tien Wang; Franck E. Nicolini
47 642 for matched controls (p < 0.001). Among common CLL treatments, average costs per patient were
Blood | 2010
Si-Tien Wang; H. Huang; Abbie Ba-Mancini; Hongliang Shi; Kristina Chen; Caroline Korves; Ravinder Dhawan; Andrew Cakana; Helgi van de Velde; Dixie-Lee Esseltine; Mei Sheng Duh
5140 for rituximab and
Blood | 2009
Si-Tien Wang; H. Huang; Hongliang Shi; Mei Sheng Duh; Kristina Chen; Eva Chang; Caroline Korves; R Dhawan; Andrew Cakana; Helgi van de Velde; Dixie-Lee Esseltine; Louis P. Garrison
953 for radiation therapy. Compared to matched controls, patients with CLL had significantly higher monthly costs during the continuing and terminal phases. This study showed that average lifetime costs to Medicare were
Value in Health | 2011
Si-Tien Wang; H. Huang; Abbie Ba-Mancini; Hongliang Shi; Kristina Chen; Caroline Korves; Ravinder Dhawan; A. Cakana; H. van de Velde; Mei Sheng Duh
87 151 for patients with CLL compared to
Blood | 2010
Leslie A Ray; Gene A. Wetzstein; Si-Tien Wang; Amy Guo; Caroline Korves; Bentley Clinton; R. Wei; Mei Sheng Duh
47 642 for matched controls without cancer, for a significant difference of
Value in Health | 2009
A Raptis; Duh; Si-Tien Wang; E Dial; I Fanourgiakis; B Fortner; Carole Paley; N Mody-Patel; M Corral; J Scott
39 509.
